Form 144 Immunome For: 6 July By Investing.com
The article is a brief financial update from Investing.com, stating "Form 144 Immunome For: 6 July". It includes the stock symbol IMNM and notes a 1.23% increase. The content appears to be a placeholder or a very short news item, possibly indicating an SEC filing.
IMNM (Nasdaq) affiliate filings report multiple share sales, including 100,000-share entries
Immunome Inc. (IMNM) affiliates have filed Form 144s reporting multiple share sales. These filings indicate an intended sale of 100,000 shares from a private placement dating back to October 2023, and recent sales including two 100,000-share entries and one 1,050-share entry by entities like ABHMC II LLC and ARSENAL BRIDGE VENTURE II-B LLC on June 30, 2026, and July 2, 2026. The filing notes the sales are procedural disclosures under securities rules, with the private placement proceeds listed as cash.
Immunome's $4.39 Million Insider Sale: A Pre-Planned Exit Amidst Robust Pipeline Momentum
Immunome director Isaac Barchas recently sold over $4.39 million in shares, but these transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating personal financial management rather than a lack of confidence. The company shows robust clinical momentum with an NDA submission for varegacestat and new ADC pipeline progress, supported by a strong cash position. Despite some institutional re-evaluation, Wall Street analysts remain overwhelmingly bullish on Immunome, with a median price target of $36.0, suggesting significant upside due to its promising pipeline.
Form 4 Immunome Inc For: 2 July
This article from Investing.com reports on a Form 4 filing for Immunome Inc., dated July 2nd. The content is brief, primarily serving as a notification about the regulatory filing related to the company. It includes information about Immunome Inc.'s stock performance, showing a 9.87% increase, along with various financial market data and popular news headlines.
Immunome director Barchas sells $4.39m in common stock By Investing.com
Immunome Inc. director Isaac Barchas indirectly sold over $4.39 million worth of common stock across several transactions on June 30 and July 2, 2026, within a price range of $21.12 to $23.33 per share. These sales, executed via Rule 10b5-1 trading plans, occurred after the stock gained 167% over the past year and is considered overvalued by InvestingPro analysis, prompting him to lock in gains. Despite the insider selling, Wall Street analysts maintain a bullish outlook on Immunome, with price targets between $30 and $40, and the company has recently made significant advancements, including an NDA submission for varegacestat and a Phase 1 trial for IM-1617.
Director-linked entities trim Immunome (IMNM) stake with 201,050-share sale
Entities associated with Immunome director Isaac Barchas sold a total of 201,050 shares of Immunome common stock on June 30 and July 2, 2026. These open-market sales were conducted under pre-arranged Rule 10b5-1 trading plans at weighted average prices ranging from $21.12 to $23.33. Following these transactions, Barchas-linked entities indirectly hold 208,504 shares, with Barchas himself directly holding an additional 103,259 shares.
Form 4 Immunome Inc For: 2 July
The article reports on a Form 4 filing for Immunome Inc. on July 2nd, without providing specific details of the filing. It is a brief news item indicating an insider transaction or a change in ownership that has been disclosed. The stock symbol associated with Immunome Inc. is IMNM.
IMNM (Nasdaq: IMNM) Rule 144 entries show 100,000-share block
Immunome Inc. (Nasdaq: IMNM) has reported sales of Common Stock under Rule 144 disclosures, including a 100,000-share block tied to a private placement from October 3, 2023. Recent secondary transactions show ABHMC II LLC selling 100,000 shares and Arsenal Bridge Venture II-B LLC selling 1,050 shares for $22,180.72, both on June 30, 2026. The filing indicates a neutral impact and sentiment, with the securities acquired via a private placement in cash.
IMNM (NASDAQ: IMNM) affiliate files to sell 55,000 shares on 07/02/2026
Immunome Inc. (NASDAQ: IMNM) filed a Form 144 notice indicating a proposed sale of 55,000 shares of common stock by an affiliate. These shares were acquired via a stock option exercise and are scheduled to be sold by Fidelity Brokerage Services LLC on July 2, 2026, with an estimated value of $1,188,000. The filing also notes a related prior sale of 55,000 shares on June 25, 2026, for $1,091,673. This serves as a regulatory notification of intent rather than a completed transaction.
Is Immunome’s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story?
Immunome (IMNM) was removed from several Russell indices in late June 2026, coinciding with insider stock sales and a Form 144 filing. This development impacts the company's shareholder base and trading liquidity, potentially making future funding more sensitive to market swings. While the clinical pipeline remains a focus, the index removal combined with existing losses and dilution risks adds complexity to Immunome's investment narrative.
IMNM - Immunome Inc Options
This article provides a detailed financial overview of Immunome Inc (IMNM), including its stock performance, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, analyst recommendations, and a summary of earnings and sales surprise data. The data is presented as of July 2, 2024, at 10:02 AM ET.
[144] Immunome Inc. SEC Filing
This article reports on an SEC Form 144 filing by Immunome Inc. (IMNM). The filing indicates a proposed sale of 100,000 shares of common stock, acquired via private placement in October 2023, with an aggregate market value of $2,104,000. The sale is to be conducted through Merrill Lynch on the Nasdaq exchange.
Form 4 Immunome Inc For: 29 June By Investing.com
This article from Investing.com announces the filing of Form 4 for Immunome Inc. on June 29. It provides the headline and mentions the associated stock symbol IMNM. The content primarily consists of market data and unrelated trending articles.
Immunome (IMNM) After Russell Index Removal Still Looks Cheap On Fair Value
Immunome (IMNM) has been removed from several Russell indexes, yet its stock has seen positive short-term returns and strong long-term momentum. Despite this removal, Simply Wall St's DCF model suggests a fair value significantly higher than its current trading price of $21.04, indicating it may still be undervalued. The company faces risks associated with its net loss and early-stage clinical assets, but its P/B ratio suggests potential upside compared to peers.
Form 4 Immunome Inc For: 29 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Immunome Inc. dated June 29. Form 4 filings are typically used to disclose changes in beneficial ownership of securities by company insiders. The brief piece includes the stock symbol IMNM and notes a 5.46% change.
Immunome (IMNM) CMO sells 55K shares after exercising options
Immunome Inc.'s Chief Medical Officer, Robert Lechleider, exercised 55,000 employee stock options at $8.73 per share and subsequently sold all 55,000 shares in open-market transactions. The sales were executed under a pre-arranged Rule 10b5-1 trading plan, with weighted average prices of $19.56 and $20.66. After these transactions, Lechleider directly holds 15,805 shares of common stock and 345,000 employee stock options.
Immunome CMO Robert Lechleider sells $1.09m in stock By Investing.com
Immunome Inc.'s Chief Medical Officer, Robert Lechleider, sold 55,000 shares of the company's common stock for approximately $1.09 million on June 25, 2026, after exercising employee stock options. Following the transactions, Lechleider directly holds 15,805 shares and retains 345,000 unexercised options. This insider sale follows significant clinical and regulatory advancements for Immunome, including progress in cancer treatments and positive analyst ratings.
Immunome CMO Robert Lechleider sells $1.09m in stock
Immunome Inc.'s Chief Medical Officer, Robert Lechleider, sold 55,000 shares of company stock for approximately $1.09 million, executed under a Rule 10b5-1 trading plan. This followed his exercise of employee stock options. Despite the sale, Lechleider still holds 15,805 shares and 345,000 unexercised options.
Immunome, Inc.(NasdaqCM: IMNM) dropped from Russell 3000E Index
Immunome, Inc. (NasdaqCM:IMNM), a clinical-stage oncology company, has been removed from the Russell 3000E Index. The company is currently developing first-in-class targeted therapies for cancer, with pipeline programs including varegacestat (Phase III), IM-1021 (Phase I), and several preclinical ADCs. This news follows recent reports of insider stock sales and progress in its clinical trials.
(IMNM) Price Dynamics and Execution-Aware Positioning
This article analyzes Immunome Inc. (NASDAQ: IMNM) using AI models to provide trading strategies and multi-timeframe signal analysis. Key findings indicate a near-term strong sentiment, mid-term neutrality, and long-term positive bias, with elevated downside risk due to a lack of long-term support signals. The report offers specific position, momentum breakout, and risk hedging strategies, including entry zones, targets, and stop losses.
Immunome, Inc. Actuals & Estimates (NASDAQ:IMNM)
This article provides a comprehensive overview of Immunome, Inc. (NASDAQ:IMNM) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights that the stock has seen a 116.76% increase over the last year, with analysts providing a price target range of $30.00 to $40.00. The article also details recent earnings and revenue figures, upcoming earnings dates, and key financial metrics like market capitalization and EBITDA.
Form 144 Immunome Inc. For: 25 June By Investing.com
This article from Investing.com reports on a Form 144 filing for Immunome Inc. on June 25th. The filing indicates a transaction related to Immunome stock. The article primarily serves as a notice of this financial event, with no further details provided in the body of the content.
IMNM Forecast — Price Target — Prediction for 2027
This article provides an in-depth forecast for Immunome, Inc. (IMNM) stock, including current price, analyst ratings, historical performance, earnings data, and future predictions. It details the company's financial metrics such as market capitalization, revenue, net income, and EBITDA, while also offering guidance on how to interpret investment data and access trading resources.
[144] Immunome Inc. SEC Filing
This article details an SEC Form 144 filing by Immunome Inc. (IMNM), indicating a proposed sale of 55,000 shares acquired through a stock option exercise, with an aggregate market value of $1,085,150.00. The filing, accepted on June 25, 2026, also provides general information about Form 144 requirements and recent news about Immunome Inc.
Does Immunome's (IMNM) New IM-1617 Trial Reveal Its Real Antibody-Drug Conjugate Ambitions?
Immunome (IMNM) has initiated a Phase 1 trial for IM-1617, an antibody-drug conjugate for advanced solid tumors, marking a significant step for its ADC platform. This trial, alongside planned IND filings for IM-1340 and IM-1335, sharpens the company's oncology focus and investment narrative. However, the article notes that investors should still consider the company's funding needs and potential dilution, as the new trial increases operational focus on safety data across multiple programs rather than fundamentally altering the risk profile.
Does Immunome's (IMNM) New IM-1617 Trial Reveal Its Real Antibody-Drug Conjugate Ambitions?
Immunome, Inc. has initiated a Phase 1 trial for IM-1617, a potential first-in-class antibody-drug conjugate for advanced solid tumors, enhancing its oncology pipeline. This development, alongside pending FDA decisions and planned IND filings, highlights the company's focus on its antibody-drug conjugate platform. The article explores how this trial impacts Immunome's investment narrative, emphasizing the need to believe in the company's ability to commercialize its pipeline despite early-stage financial challenges.
Does Immunome's (IMNM) New IM-1617 Trial Reveal Its Real Antibody-Drug Conjugate Ambitions?
Immunome, Inc. has initiated a Phase 1 trial for IM-1617, a potential first-in-class antibody-drug conjugate (ADC) for advanced solid tumors, enhancing its oncology pipeline. This development, alongside planned IND filings for other ADCs, sharpens the company's investment narrative, focusing on its ADC platform. Despite limited revenue and ongoing losses, the trial introduces a genuine clinical catalyst, though significant questions remain regarding funding, potential dilution, and the ability to achieve profitability.
Immunome (IMNM) Stock Could Be Below Fair Value After Phase 1 Trial Start
Immunome (IMNM) has initiated a Phase 1 trial for an antibody drug conjugate targeting solid tumors, leading to mixed stock performance with an 18.38% dip over the last month but a 114.17% return over the past year. Despite current unprofitability, Simply Wall St's Discounted Cash Flow (DCF) model estimates Immunome to be undervalued, projecting a fair value of $153.32 against a recent close of $18.74, largely based on future pipeline expectations. However, the company faces risks from ongoing losses and reliance on early-stage clinical assets.
Immunome Inc (IMNM) Valuation: PE, PB & Fair Value Analysis
Immunome Inc (IMNM) has a current valuation score of 5.79, placing it 373 out of 389 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -7.86, showing a significant fluctuation compared to its recent high and low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Immunome Inc (IMNM) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Immunome Inc (IMNM), highlighting its current price momentum score of 6.90 within the Biotechnology & Medical Research industry. It identifies a trading range with resistance at $22.08 and support at $16.62. The analysis also details various technical indicators like MACD, RSI, and Moving Averages, which collectively suggest a "Sell" signal for the stock based on current data.
Immunome CFO Max Rosett sells $1.09m in stock
Immunome Inc.'s CFO, Max Rosett, sold 60,000 shares of company stock worth $1.09 million on June 15, 2026, under a pre-arranged trading plan, after exercising stock options for the same number of shares. This sale follows a year of significant stock price appreciation for Immunome and comes amidst positive clinical trial results for its cancer therapies, leading to raised price targets by analysts.
Immunome CFO Max Rosett sells $1.09m in stock
Immunome Inc.'s CFO, Max Rosett, sold 60,000 shares of company stock for over $1.09 million on June 15, 2026, after exercising stock options. This sale, conducted via a Rule 10b5-1 trading plan, follows a 100% return for Immunome shares over the past year, though the stock is currently considered slightly overvalued. The company recently announced positive developments, including the dosing of the first patient in a Phase 1 trial for a new cancer therapeutic and promising results from its Phase 3 RINGSIDE trial for varegacestat, leading to increased price targets from analysts.
Immunome (IMNM) CFO uses options, sells 60,000 shares under 10b5-1 plan
Immunome Inc.'s CFO, Max Rosett, executed an exercise-and-sale transaction, exercising options for 60,000 shares at $1.05 per share and simultaneously selling those 60,000 shares at a weighted average price of $18.23. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, leave Rosett with 54,037 directly held shares. The transaction is categorized as neutral in impact and sentiment.
(IMNM) as a Liquidity Pulse for Institutional Tactics
This article analyzes Immunome Inc. (IMNM) using AI models, highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three institutional trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Short Risk Hedging Strategy. The analysis also includes multi-timeframe signal data for support and resistance levels.
How Immunome’s First-in-Human IM-1617 ADC Trial At Immunome (IMNM) Has Changed Its Investment Story
Immunome (IMNM) recently initiated a first-in-human Phase 1 trial for its ADC candidate, IM-1617, in advanced solid tumors, signifying a crucial step in the company's transition into a clinically validated asset developer. This move, leveraging Immunome's proprietary HC74 TOP1 inhibitor payload, reinforces its commitment to building an ADC franchise. While the FDA review of varegacestat remains a near-term catalyst, the IM-1617 trial strengthens the importance of future ADC data readouts as secondary drivers for the investment narrative, albeit with persistent risks around losses and potential dilution.
How Immunome’s First-in-Human IM-1617 ADC Trial At Immunome (IMNM) Has Changed Its Investment Story
Immunome, Inc. has initiated its first-in-human Phase 1 trial for IM-1617, an antibody-drug conjugate for advanced solid tumors, marking a significant step in expanding its ADC pipeline. This development shifts Immunome's investment narrative from a pure R&D story to one with clinically validated assets, reinforcing its ADC franchise strategy. While the FDA review of varegacestat remains a key near-term catalyst, IM-1617’s progress also highlights inherent risks like persistent losses and potential future dilution.
How Immunome’s First-in-Human IM-1617 ADC Trial At Immunome (IMNM) Has Changed Its Investment Story
Immunome (IMNM) has dosed its first patient in a Phase 1 trial for IM-1617, an antibody-drug conjugate for advanced solid tumors, signifying a shift in its investment narrative from pure R&D to a company with clinically validated assets. This development reinforces Immunome's strategy to build a robust ADC franchise, supported by plans for additional investigational new drug submissions in 2026. While the FDA review of varegacestat remains a near-term catalyst, the advancement of IM-1617 into the clinic boosts the importance of ADC data readouts as secondary growth drivers for the company.
IMNM (NASDAQ: IMNM) director plans to sell 60,000 shares via option
Immunome Inc. (NASDAQ: IMNM) reported a proposed sale of 60,000 shares of common stock by means of a stock option exercise, planned for June 15, 2026, which will be a cash transaction processed by Fidelity Brokerage Services LLC. This Form 144 filing also noted a prior sale by Max Rosett of 65,000 shares on April 2, 2026, for $1,425,084.64. The filing is considered a routine insider disposition and does not reflect an operational update for the company.
[Form 4] Immunome Inc. Insider Trading Activity
Immunome Inc. reported a Form 4 insider transaction detailing a stock option grant to director James P. Boylan. This option covers 9,897 shares of common stock with an exercise price of $18.16 and vests in four equal quarterly installments starting June 10, 2026, contingent on continuous service. Mr. Boylan disclaims beneficial ownership, holding the securities for Enavate Sciences, LP.
Immunome (IMNM) director granted stock options on 9,897 common shares
Immunome Inc. director Jean Jacques Bienaimé was granted stock options for 9,897 common shares, with an exercise price of $18.16 per share and an expiration date of June 9, 2036. The options will vest in four equal quarterly installments beginning June 10, 2026, contingent on his continued service to the company. This transaction is a compensation-related award rather than an open-market purchase.
Immunome (IMNM) director-linked entity awarded 9,897 stock options at $18.16 strike
Immunome Inc. (IMNM) has granted a director stock option for 9,897 shares at an exercise price of $18.16 per share, expiring on June 9, 2036. The options are linked to director Isaac Barchas, but he disclaims beneficial ownership, with the securities held for the benefit of Arsenal Bridge Ventures. The options will vest in four equal quarterly installments beginning June 10, 2026, contingent on Barchas's continuous service.
Immunome (IMNM) director Carol Schafer receives grant of 9,897 stock options
Immunome Inc. director Carol Schafer was granted 9,897 stock options as part of her compensation, with an exercise price of $18.16 per share and an expiration date of June 9, 2036. The options will vest in four equal quarterly installments beginning June 10, 2026, provided she maintains continuous service with the company. This transaction is a compensation award, not an open-market purchase or sale.
[Form 4] Immunome Inc. Insider Trading Activity
Immunome Inc. director Philip Wagenheim was granted 9,897 director stock options, allowing him to purchase common stock at an exercise price of $18.16 per share. These options are set to expire on June 9, 2036, and will vest in four equal quarterly installments beginning June 10, 2026, contingent on his continued service to the company. The Form 4 filing details this transaction, noting the direct ownership and vesting schedule of the stock options.
Immunome (IMNM) 2026 meeting: directors elected, pay and auditor votes pass
Immunome, Inc. announced the results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders elected three Class III directors, ratified Ernst & Young LLP as the independent registered public accounting firm, and approved named executive officer compensation on an advisory basis. They also expressed a preference for annual say-on-pay votes, which the company will adopt.
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Immunome, Inc. announced that the first patient has been dosed in its Phase 1 trial for IM-1617, a potential first-in-class antibody-drug conjugate (ADC) targeting advanced solid tumors. The trial will assess the safety, tolerability, pharmacokinetics, and anti-tumor activity of IM-1617, which incorporates Immunome’s proprietary topoisomerase I inhibitor payload, HC74. This milestone advances Immunome's ADC platform, with further IND submissions planned for other ADC programs (IM-1340 and IM-1335) later in 2026.
Immunome Doses First Patient in Phase 1 Trial of Potential First-in-Class ADC IM-1617 for Advanced Solid Tumors
Immunome has dosed the first patient in a Phase 1 clinical trial for IM-1617, a potential first-in-class antibody-drug conjugate (ADC) designed to treat advanced solid tumors. This trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1617, which combines an undisclosed solid tumor target with Immunome's proprietary HC74 topoisomerase I inhibitor payload. The company plans to submit investigational new drug applications for two additional ADC candidates in mid- and late-2026, further expanding its oncology pipeline.
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Immunome, Inc. announced that the first patient has been dosed in its Phase 1 clinical trial for IM-1617, a potential first-in-class antibody-drug conjugate (ADC) designed for advanced solid tumors. This ADC incorporates Immunome’s proprietary topoisomerase I (TOP1) inhibitor payload, HC74. The company also anticipates filing investigational new drug (IND) submissions for two other ADC programs, IM-1340 and IM-1335, in mid- and late 2026, respectively.
Immunome (IMNM) director receives 9,897 stock options at $18.16 strike price
Immunome Inc. director Sandra M. Swain was granted 9,897 stock options with an exercise price of $18.16 per share, set to expire on June 9, 2036. The options will vest in four equal quarterly installments starting June 10, 2026, provided she remains with the company. This transaction is publicly documented in a Form 4 SEC filing, detailing the option grant and vesting schedule.
[Form 4] Immunome Inc. Insider Trading Activity
Immunome Inc. (IMNM) reported insider trading activity via a Form 4 filing, showing five transactions by BIENAIME JEAN JACQUES, identified as a Director. The transactions included both purchases and sales of common stock on June 5, 2026, totaling 10,500 shares bought and 10,500 shares sold, with a footnote explaining a short-swing transaction and profit payment of $155 to the issuer.
Immunome director Bienaime sells $203k, buys $204k in same-day trades
Immunome Inc. director Jean Jacques Bienaime executed same-day trades on June 5, 2026, selling 10,500 shares for $203,820 and simultaneously buying 10,500 shares for $204,260. A short-swing profit of $155, which Bienaime agreed to pay back to Immunome, was realized during these transactions. This news comes as Immunome progresses with its desmoid tumor drug, varegacestat, showing promising Phase 3 results and receiving positive analyst ratings and price target increases from Truist Securities and Barclays.
